BlackRock’s Biocept, Inc. BIOC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-5,261
Closed -$6.58K 5555
2023
Q3
$6.58K Hold
5,261
﹤0.01% 5225
2023
Q2
$6.37K Sell
5,261
-3
-0.1% -$17 ﹤0.01% 5292
2023
Q1
$53.7K Hold
5,264
﹤0.01% 5102
2022
Q4
$83.7K Hold
5,264
﹤0.01% 5096
2022
Q3
$145K Hold
5,264
﹤0.01% 5065
2022
Q2
$148K Sell
5,264
-1,385
-21% -$63.1K ﹤0.01% 5116
2022
Q1
$463K Buy
6,649
+224
+3% +$17.6K ﹤0.01% 4894
2021
Q4
$698K Buy
6,425
+46
+0.7% +$5.3K ﹤0.01% 4776
2021
Q3
$767K Sell
6,379
-26
-0.4% -$3.03K ﹤0.01% 4634
2021
Q2
$805K Buy
6,405
+17
+0.3% +$2.3K ﹤0.01% 4573
2021
Q1
$975K Hold
6,388
﹤0.01% 4509
2020
Q4
$851K Hold
6,388
﹤0.01% 4254
2020
Q3
$845K Sell
6,388
-1,932
-23% -$390K ﹤0.01% 4151
2020
Q2
$1.78M Buy
8,320
+8,232
+9,355% +$1.18M ﹤0.01% 3856
2020
Q1
$8K Hold
88
﹤0.01% 4738
2019
Q4
$8K Hold
88
﹤0.01% 4763
2019
Q3
$22K Hold
88
﹤0.01% 4639
2019
Q2
$29K Hold
88
﹤0.01% 4642
2019
Q1
$30K Hold
88
﹤0.01% 4549
2018
Q4
$23K Hold
88
﹤0.01% 4566
2018
Q3
$73K Hold
88
﹤0.01% 4501
2018
Q2
$159K Buy
88
+1
+1% +$2.02K ﹤0.01% 4367
2018
Q1
$230K Buy
87
+1
+1% +$3.75K ﹤0.01% 4181
2017
Q4
$534K Buy
86
+1
+1% +$7.91K ﹤0.01% 4042
2017
Q3
$940K Hold
85
﹤0.01% 3931
2017
Q2
$1.04M Sell
85
-1
-1% -$14.1K ﹤0.01% 3841
2017
Q1
$1.65M Buy
+86
New +$1.46M ﹤0.01% 3711

BlackRock's BIOC Position: Q4 2023 in Review

BlackRock sold out of Biocept, Inc. (BIOC) in Q4 2023, closing a stake of 5,261 shares — an estimated $6.58K sold.

BlackRock first reported a position in BIOC in Q1 2017 and held it in 27 quarters. The position peaked at $1.78M in Q2 2020. 0 funds tracked by Wall St. Rank hold BIOC as of Q4 2023.

  • BlackRock reported no remaining Biocept, Inc. position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 5,261 Biocept, Inc. shares in Q4 2023, an estimated $6.58K.
  • BlackRock first reported a position in Biocept, Inc. in Q1 2017 and held it in 27 quarters.
  • BlackRock's Biocept, Inc. position peaked at $1.78M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Biocept, Inc. as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.